“…Multicomponent CB Banking using platelets, plasma and red blood cells from a proportion of currently discarded CB units could contribute to increasing the therapeutic value and reducing the financial deficit of public CB banking programs ( Querol et al, 2021 ; Scaradavou, 2021 ). International regulatory harmonization and multicenter, large laboratory and clinical studies with sufficient statistical power are necessary to support the preliminary evidences reported in the literature ( Bhattacharya et al, 2001 ; Bhattacharya, 2006 ; Khodabux et al, 2008 ; Khodabux and Brand, 2009 ; Khodabux et al, 2011 ; Hassall et al, 2012 ; Erdem et al, 2014 ; Rosso et al, 2014 ; Versura et al, 2014 ; Yoon, 2014 ; Bianchi et al, 2015 ; Hassall et al, 2015 ; Sharma et al, 2016 ; Piccin et al, 2017a ; Piccin et al, 2017b ; Giannaccare et al, 2017 ; Volpe et al, 2017 ; Bianchi et al, 2018 ; Buzzi et al, 2018 ; Campos et al, 2018 ; Gelmetti et al, 2018 ; Neema, 2018 ; Sarin et al, 2018 ; Sindici et al, 2018 ; Teofili et al, 2018 ; Bianchi et al, 2020 ; Bisceglia et al, 2020 ; Samarkanova et al, 2020c ; Giannaccare et al, 2020 ; González et al, 2020 ; Lopriore et al, 2020 ; Teofili et al, 2020 ; Volpe et al, 2020 ; Samarkanova et al, 2021 ; Torkamaniha et al, 2021 ) and achieve these important goals.…”